Apr 17, 2017

Tricking bacteria into killing themselves

Francisco Bengoa via Flickr CC

The CRISPR gene-editing technology could be used to target specific bacteria that cause fatal, drug-resistant infections in humans, according to MIT Technology Review.

Problem to be solved: Antibiotic-resistant bacteria are a danger to patients and lead to increased health care costs, according to the WHO. And more than 70% of the bacteria that cause infections in hospitals are resistant to at least one of the antibiotics usually used to treat them, per the FDA.

Eligo Biosciences in Paris and Locus Biosciences in North Carolina have started working on developing CRISPR-based antibiotics commercially.

How it would work: The patient would take a probiotic containing viruses called bacteriophage that have modified CRISPR messages. The CRISPR messages would transfer instructions specifically to drug-resistant bacteria to edit their own DNA in a way that tricks them into killing themselves off. Beneficial bacteria wouldn't be touched.

Jan-Peter Van Pijkeren, a food scientist at the University of Wisconsin, specifically wants to target the bacterium Clostridium difficile, which is on the CDC's list of urgent drug-resistant threats.

Potential snags: Each kind of bacteriophage tends to only infect certain bacteria, so the CRISPR technology would need to work with more types of bacteriophage in order to fight different infections.

Go deeper

GOP sees more hurdles for Trump as coronavirus crisis drags on

Photo: Alex Wong/Getty Images

Republicans are increasingly concerned not only about President Trump’s daily briefings but also his broader plan to ease the nation out of the virus crisis and back to work. This concern is acute — and spreading. 

Why it matters: Trump can easily address the briefing worries by doing fewer, but the lackluster bounce-back planning is what worries Republicans most. 

Pandemic forces startups to shift gears

Illustration: Eniola Odetunde/Axios

Spaces CEO Brad Herman had an early warning about COVID-19 because his startup supplies VR attractions to a number of theme parks in China. Realizing that the business he spent the last few years building was going to evaporate, Herman quickly found a new way to apply his team's know-how: helping companies host Zoom teleconferences in VR.

Why it matters: Many startups are rethinking the viability of their core businesses in the wake of the coronavirus. Spaces' move is one of many such pivots likely to crop up in the coming months.

International coronavirus treatment trial uses AI to speed results

Hydroxychloroquine is one of the drugs that will be included in the trial. Photo: John Philips/Getty Images

The first hospital network in the U.S. has joined an international clinical trial using artificial intelligence to help determine which treatments for patients with the novel coronavirus are most effective on an on-going basis.

Why it matters: In the midst of a pandemic, scientists face dueling needs: to find treatments quickly and to ensure they are safe and effective. By using this new type of adaptive platform, doctors hope to collect clinical data that will help more quickly determine what actually works.